JP2024540152A - 抗ｃｔｌａ－４抗体投与レジメン - Google Patents

抗ｃｔｌａ－４抗体投与レジメン Download PDF

Info

Publication number
JP2024540152A
JP2024540152A JP2024525557A JP2024525557A JP2024540152A JP 2024540152 A JP2024540152 A JP 2024540152A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024540152 A JP2024540152 A JP 2024540152A
Authority
JP
Japan
Prior art keywords
cancer
ctla
antibody
seq
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540152A5 (enExample
Inventor
リウ、ヤン
チョン、パン
デヴェンポート、マーティン
Original Assignee
オンコシーフォー、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコシーフォー、インク． filed Critical オンコシーフォー、インク．
Publication of JP2024540152A publication Critical patent/JP2024540152A/ja
Publication of JP2024540152A5 publication Critical patent/JP2024540152A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024525557A 2021-10-29 2022-10-28 抗ｃｔｌａ－４抗体投与レジメン Pending JP2024540152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
US63/273,660 2021-10-29
PCT/US2022/078875 WO2023077069A1 (en) 2021-10-29 2022-10-28 Anti-ctla-4 antibody dosing regimens

Publications (2)

Publication Number Publication Date
JP2024540152A true JP2024540152A (ja) 2024-10-31
JP2024540152A5 JP2024540152A5 (enExample) 2025-11-07

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525557A Pending JP2024540152A (ja) 2021-10-29 2022-10-28 抗ｃｔｌａ－４抗体投与レジメン

Country Status (9)

Country Link
EP (1) EP4422685A4 (enExample)
JP (1) JP2024540152A (enExample)
KR (1) KR20240099187A (enExample)
CN (1) CN118176021A (enExample)
AU (1) AU2022377644A1 (enExample)
CA (1) CA3234351A1 (enExample)
MX (1) MX2024004429A (enExample)
TW (1) TW202325738A (enExample)
WO (1) WO2023077069A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121358769A (zh) * 2023-05-17 2026-01-16 昂科医药 Ph敏感性抗ctla-4抗体及其用途
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Also Published As

Publication number Publication date
MX2024004429A (es) 2024-05-06
EP4422685A1 (en) 2024-09-04
CA3234351A1 (en) 2023-05-04
EP4422685A4 (en) 2025-12-03
AU2022377644A1 (en) 2024-05-16
KR20240099187A (ko) 2024-06-28
CN118176021A (zh) 2024-06-11
WO2023077069A1 (en) 2023-05-04
TW202325738A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
JP7519477B2 (ja) 非小細胞肺がんを治療するための抗ｂ７－ｈ１および抗ｃｔｌａ－４抗体
AU2021221560B2 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
JP2022184998A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2024540152A (ja) 抗ｃｔｌａ－４抗体投与レジメン
EP4469477A1 (en) Combination therapy for hepatocellular carcinoma
US20260092112A1 (en) Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
HK40106641A (zh) 抗ctla-4抗体给药方案
TW202517679A (zh) 以抗ｉｌｔ２抗體治療癌症
HK40013014A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK40006436B (en) Use of glutamate modulating agents with immunotherapies to treat cancer
HK40006436A (en) Use of glutamate modulating agents with immunotherapies to treat cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251028